Dr. Danny Hadaya is an Oral and Maxillofacial Surgery resident at UCLA. He completed his DDS and PhD in Oral Biology at the UCLA School of Dentistry. Danny’s PhD dissertation focused on Medication-Related Osteonecrosis of the Jaws, which has given him significant background in basic and translational bone biology. Danny has published numerous original research manuscripts, and received a prestigious NIH/NIDCR Fellowship during his PhD. He is interested in hard and soft tissue regeneration and is committed to a career as a clinician-scientist at an academic institution following completion of his residency.
In an era dominated by reconstructive biotechnology, much effort has been placed into development of biomaterials that mimic autologous bone grafting properties. Development of these biomaterials provides clinicians with alternate methods to reconstruct maxillofacial defects without associated donor site morbidity. Despite various advances, the gold standard materials remain autologous tissue. Autologous bone is the only graft material that provides osteogenic properties, while most other biomaterials are osteoconductive. Platelet-Rich Fibrin (PRF) is a second-generation platelet concentrate, first developed for use in Oral and Maxillofacial Surgery in 2000. Biologically, PRF is a collection of platelets, cytokines, and growth factors that are derived from whole blood. Here, we will assess the ability of i-PRF to enhance bone regeneration in the presence of a 1) autogenous bone graft, 2) an allogenic bone graft, and 3) a xenogeneic bone graft.